Yumanity chairman Tony Coles (L) and CEO Richard Peters
Following deep cuts, Yumanity strikes a deal to sell drugs to J&J, hands the keys to Genentech-partnered Kineta
Yumanity has found that “strategic alternative” it started searching for early this year as its share price shriveled, forcing deep staff cuts.
The suffering biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.